1. Medtech Insight
  2. >>Archive

Brainsway Closes Gap Between Devices And Drugs With Noninvasive Deep Brain Stimulation

Following a series of private investments and strategic acquisitions, Brainsway Ltd. announced it had received CE mark approval for a new therapy for chronic neuropathic pain, bringing another potential neurostimulation treatment to market in Europe. Meanwhile, the company reported positive interim results on its clinical trial of a treatment for obsessive compulsive disorder, adding to positive results from a pivotal multicenter trial studying its therapy for major depression. These trials validate a new device treatment for conditions that neurologists and psychiatrists typically treat with drugs.

Deep brain stimulation technologies continue to gather momentum. Following a series of private investments and strategic acquisitions, Brainsway Ltd. announced in early July that it had received CE mark approval for a new therapy for chronic neuropathic pain, bringing another potential neurostimulation treatment to market in Europe. Meanwhile, the company reported positive interim results on its clinical trial of a treatment for obsessive compulsive disorder, adding to positive results from a pivotal multicenter trial studying its therapy for major depression. These trials validate a new device therapy for conditions that neurologists and psychiatrists typically treat with drugs.

Many of the diseases that originate in the brain – Parkinson’s disease and other movement disorders, epilepsy, major depressive disorder, obsessive compulsive disorder, bipolar disorder, schizophrenia – do not respond well to drug therapies, leaving an opportunity for device companies developing deep brain stimulation treatments. (SeeAlso see "Deep Brain Provides Stimulating Market" - Medtech Insight, 26 March, 2012..) However, there is a wide gulf between pills that a patient swallows and current deep brain stimulation therapies from companies like Medtronic PLC and St

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By Ashley Yeo

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.

23andMe Purchase Will Let Regeneron Scale Drug Development

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.